Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson’s Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study
Sign Up to like & getrecommendations! Published in 2021 at "Neurology and Therapy"
DOI: 10.1007/s40120-021-00251-6
Abstract: In a pivotal study, apomorphine sublingual film (APL; KYNMOBI®) was an effective and generally well-tolerated on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD), approved across the dose range of 10–30 mg. Pharmacokinetics… read more here.
Keywords: bioavailability; apo apo; apomorphine formulations; open label ... See more keywords